Intellia's Data Has Underlined Huge Potential Of Gene Therapeutics And There Will Be More Soon
Summary :
Intellia is a gene therapy specialist pioneering CRISPR-Cas9 technology.
Its recently released data in ATTR Amyloidosis stunned analysts, showing mean reduction in TTR Serum levels of up to 96%.
This was the first ever clinical proof of the safety and efficacy of an in-vivo CRISPR genome editing technology in a human trial, and sent Intellia's share price up by >100%.
Intellia will release more data from the trial and initiate a single-dose expansion cohort before the end of the year.
SOURCE : Edmund Ingham, Aug. 31, 2021, Seeking Alpha
seekingalpha.com/art...of-gene-therapeutics
Summary :
Intellia is a gene therapy specialist pioneering CRISPR-Cas9 technology.
Its recently released data in ATTR Amyloidosis stunned analysts, showing mean reduction in TTR Serum levels of up to 96%.
This was the first ever clinical proof of the safety and efficacy of an in-vivo CRISPR genome editing technology in a human trial, and sent Intellia's share price up by >100%.
Intellia will release more data from the trial and initiate a single-dose expansion cohort before the end of the year.
SOURCE : Edmund Ingham, Aug. 31, 2021, Seeking Alpha
seekingalpha.com/art...of-gene-therapeutics
订单已取消